| Literature DB >> 34610799 |
Shayan Chen1,2, Jiyu Shi3, Minghui Chen1, Jun Ma1, Zhaowei Zeng1, Rui Wang1, Yunfeng Cui4, Xue Gao5.
Abstract
BACKGROUND: Infection in patients with acute pancreatitis, especially severe acute pancreatitis patients, is a common and important phenomenon, and the distributions and drug resistance profiles of bacteria causing biliary infection and related risk factors are dynamic. We conducted this study to explore the characteristics of and risk factors for bacterial infection in the biliary tract to understand antimicrobial susceptibility, promote the rational use of antibiotics, control multidrug-resistant bacterial infections and provide guidance for the treatment of acute pancreatitis caused by drug-resistant bacteria.Entities:
Keywords: Acute pancreatitis; Biliary pathogens; Gram-negative bacteria; Multidrug-resistant bacteria; Risk factors
Mesh:
Substances:
Year: 2021 PMID: 34610799 PMCID: PMC8493750 DOI: 10.1186/s12866-021-02332-w
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Fig. 1The distribution and proportion of pathogenic bacteria in AP patients. A The distribution and proportion of pathogenic bacteria in 120 cases AP patients. B The distribution and proportion of pathogenic bacteria in 120 cases AP patients by dividing of MDRO, Enterobacteriaceae and Non-fermenter bacteria
Fig. 2Drug resistance analysis of main Gram-negative pathogenic bacteria in AP patients. A Drug resistance analysis of Escherichia coli. B Drug resistance analysis of Acinetobacter baumannii. C Drug resistance analysis of Klebsiella pneumoniae. D Drug resistance analysis of Pseudomonas aeruginosa
Fig. 3Analysis of drug resistance rates of biliary enteroderaceae and non-fermentative bacteria MDRO in AP patients. A Drug resistance analysis of Gram-negative enterobacteriaceae MDRO. B Drug resistance analysis of Gram-negative non-fermentation MDRO
Single factor analysis of risk factors for bile Gram - negative MDRO infection in AP patients
| Dangerous factor | MDRO group ( | Non-MDRO group ( | t value / Z value / χ2 value | |
|---|---|---|---|---|
| Age (Years) | 60.62 ± 14.01 | 65.70 ± 18.22 | 0.8969a | 0.3761 |
| Hospital stays (Day) | 35.65 ± 26.58 | 15.26 ± 14.25 | −3.211b | <0.001 |
| Duration of antimicrobial use (Day) | 28.44 ± 25.41 | 12.47 ± 10.98 | −4.545c | <0.001 |
| Types of antimicrobial agents used (Type) | 4.58 ± 3.22 | 2.40 ± 1.57 | −4.106d | <0.001 |
| Gender (Male) | 30 | 10 | 0.954e | 0.791 |
| Use of third or fourth generation Cephalosporins | 44 | 8 | 0.881f | <0.001 |
| Use of Carbapenems | 48 | 6 | 21.65g | <0.001 |
| Invasive operation | 40 | 6 | 1.050h | <0.001 |
| Ventilation | 6 | 2 | 1.352i | 0.066 |
| Operation | 30 | 10 | 0.592j | 0.541 |
| Combined with biliary tract disease | 10 | 8 | 15.472k | <0.001 |
| Associated abdominal infection | 20 | 6 | 0.683l | 0.539 |
| Combined diabetes | 10 | 4 | 0.852m | 0.594 |
| Complicated with malignant tumor | 0 | 0 | 3.246n | 0.800 |
| Combined with COPD or respiratory failure | 4 | 0 | 4.615o | 0.763 |
awas t value of T test, b-dwere Z value of Kruskal-Wallis Test, respectively, e-owere χ2 value
Multivariate logistic regression analysis of bile Gram - negative MDRO infection in AP patients
| Risk factors | Partial regression coefficient | Standard error | Wald | OR value | 95% CI | |
|---|---|---|---|---|---|---|
| Hospital stays | −0.018 | 0.014 | 0.987 | 0.594 | 1.172 | 0.865–1.479 |
| Duration of antimicrobial use | 0.034 | 0.144 | 1.002 | 0.951 | 1.095 | 0.921–1.268 |
| Types of antimicrobial agents used | 0.411 | 0.197 | 1.905 | 0.220 | 1.112 | 0.819–1.405 |
| Third or fourth generation cephalosporins | 0.957 | 0.157 | 2.456 | 0.040 | 2.120 | 0.955–3.287 |
| Carbapenems | 0.885 | 0.386 | 0.566 | 0.112 | 1.579 | 0.967–2.191 |
| Invasive operation | −0.157 | 0.234 | 0.020 | 0.812 | 1.562 | 0.657–2.468 |
| Combined with biliary tract disease | 0.592 | 0.805 | 0.244 | 0.620 | 1.364 | 0.247–2.482 |